PBLS Parabilis Medicines, Inc.

Fundamentals / CIK 0001657677 / USD

Parabilis Medicines, Inc. reported $1.13B in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open PBLS in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for PBLS.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Revenue $2.11M $148K -- $0 $0 --
Research & Development $45.60M $39.38M -- $28.20M $30.13M --
Total Operating Expenses $56.85M $51.03M -- $34.84M $36.52M --
Operating Income -$54.74M -$50.89M -- -$34.84M -$36.52M --
EBITDA -$54.14M -$50.29M -- -$34.74M -$36.32M --
Interest Income $10.37M $4.19M -- $711K $1.05M --
Interest Expense $124K $210K -- $398K $396K --
Net Income -$44.49M -$52.46M -$45.32M -$33.48M -$34.81M -$38.33M
Basic EPS -$0.36 -$2.32 -- -$21.66 -$22.28 --
Diluted EPS -$0.36 -$2.32 -- -$21.66 -$22.28 --
Basic Shares Outstanding 123.6M 28.9M -- 2.0M 2.0M --
Diluted Shares Outstanding 123.6M 28.9M -- 2.0M 2.0M --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for PBLS.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2025-12-31
Cash & Cash Equivalents $521.2M $1.09B $27.71M
Short-Term Investments $350.4M $33.64M $0
Cash & Short-Term Investments $871.6M $1.12B $27.71M
Accounts Receivable, Net $443K -- $0
Total Current Assets $879.0M $1.13B $29.36M
Property, Plant & Equipment, Net $9.51M $6.72M $6.71M
Long-Term Investments $201.3M -- $0
Total Non-Current Assets $252.2M $49.87M $51.46M
Total Assets $1.13B $1.18B $80.82M
Accounts Payable $20.21M $18.52M $17.27M
Short-Term Debt $2.00M $5.71M $13.08M
Deferred Revenue (Current) $13.54M $10.37M $0
Total Current Liabilities $68.26M $62.84M $56.79M
Long-Term Debt -- $700K $600K
Deferred Revenue (Non-Current) $27.30M $31.15M $0
Total Non-Current Liabilities $58.64M $64.69M $40.55M
Total Liabilities $126.9M $127.5M $97.34M
Total Debt (incl. Leases) $41.83M $48.21M $59.30M
Common Stock $12K $12K $0
Retained Earnings -$683.8M -$639.3M -$541.5M
Accumulated Other Comp. Income -$1.91M -$18K $0
Total Stockholders' Equity $1.00B $1.05B -$526.5M
Total Equity $1.00B $1.05B -$526.5M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for PBLS.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$44.49M -$52.46M -$45.32M -$33.48M -$34.81M -$38.33M
Depreciation & Amortization $600K $600K -- $100K $200K --
Stock-Based Compensation $2.74M $3.63M -- $820K $823K --

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for PBLS.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 12.88x 17.91x -- -- -- --
Quick Ratio 12.78x 17.83x -- -- -- --
Debt to Equity 0.04x 0.05x -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0001657677) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:18 UTC · Open in terminal